

Table S3. General characteristics of all patients at long-term care facilities according to therapeutic agent used

Variable	Paxlovid	Others ^{a)}	Non-treatment	Others ^{a)} vs. Paxlovid	Non-treatment vs Paxlovid
	Total (%)	Total (%)	Total (%)	p-value	p-value
Total (n=914)	623 (100)	95 (100)	196 (100)		
Sex				0.359	0.096
Male	303 (48.6)	51 (53.7)	82 (41.8)		
Female	320 (51.4)	44 (46.3)	114 (58.2)		
Age (y)				0.107	0.182
< 60	38 (6.1)	11 (11.6)	18 (9.2)		
60–74	131 (21.0)	22 (23.2)	33 (16.8)		
≥ 75	454 (72.9)	62 (65.3)	145 (74.0)		
Vaccination status				< 0.001	0.606
Unvaccinated	92 (14.8)	20 (21.1)	30 (15.3)		
1 Dose	26 (4.2)	2 (2.1)	11 (5.6)		
2 Doses					
Total	135 (21.7)	38 (40.0)	35 (17.9)		
< 90 days	67 (49.6)	22 (57.9)	11 (31.4)		
≥ 90 days	68 (50.4)	16 (42.1)	24 (68.6)		
3 Doses					
Total	370 (59.4)	35 (36.8)	120 (61.2)		
< 90 days	174 (47.0)	17 (48.6)	74 (61.7)		
≥ 90 days	196 (53.0)	18 (51.4)	46 (38.3)		
Severity					
Severe illness or death	23 (3.7)	6 (6.3)	14 (7.1)	0.226	0.042
Death	22 (3.5)	5 (5.3)	11 (5.6)	0.409	0.409

Data are presented as n (%).

^{a)}Remdesivir, Regkirona.